In patients with reduced LVEF, clinical congestion, or other predictors of HF after MI, SGLT2 inhibitors may have a role in attenuating remodeling and preventing progression to symptomatic HF, aligning with their proven efficacy in established HF populations. Here, SLC5A2 is linked to hydrops fetalis.